Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

EU Decision Time For Teclistamab & Seven Other Drugs; Incyte Withdraws Parsaclisib Filing

18 Jul 2022

• By Neena Brizmohun

Question marks background. High resolution 3d render — Companies may soon learn if their drugs will be recommended for EU approval • Source: Alamy

Related Content

Keeping Track: US FDA Okays Alnylam’s siRNA Amvuttra, Alopecia Claim For Lilly’s Olumiant; Sierra Submits Momelotinib

21 Jun 2022

Keeping Track: Pluvicto Boosts Novartis In Radiotherapy; BMS Builds Out IO Estate With Opdualag

25 Mar 2022

Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise

13 May 2022

Keeping Track Of Withdrawals: Libtayo, Parsaclisib Applications Pulled Due To Postmarketing Issues

28 Jan 2022

Related Companies

Janssen Pharmaceutical Cos.

Alnylam Pharmaceuticals Inc.

Eli Lilly and Company

Bristol Myers Squibb Company

Incyte Corporation

Additional Topics

Europe Approvals Drug Review Regulation Review Pathway Cancer Metabolic Disorders Neurology Orthopedics

More from Europe

More from Geography

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.